Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

被引:34
作者
Horowitz, Mia [1 ]
Braunstein, Hila [1 ]
Zimran, Ari [2 ,3 ]
Revel-Vilk, Shoshana [2 ,3 ]
Goker-Alpan, Ozlem [4 ]
机构
[1] Tel Aviv Univ, Schmunis Sch Biomed & Canc Res, IL-69978 Tel Aviv, Israel
[2] Shaare Zedek Med Ctr, Gaucher Unit, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA
关键词
Gaucher disease; Glucocerebrosidase (GCase); Parkinson disease; Misfolding; Unfolded Protein Response (UPR); UNFOLDED PROTEIN RESPONSE; SPHINGOLIPID ACTIVATOR PROTEINS; HUMAN GLUCOCEREBROSIDASE GENE; ENZYME REPLACEMENT THERAPY; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; BETA-GLUCOSIDASE; GBA MUTATIONS; RECOMBINANT GLUCOCEREBROSIDASE; SUBSTANTIA-NIGRA;
D O I
10.1016/j.addr.2022.114402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-beta-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is a-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in similar to 5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes a-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of a-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Parkinson's disease in women: Mechanisms underlying sex differences
    Vaidya, Bhupesh
    Dhamija, Kritika
    Guru, Priyanka
    Sharma, Shyam Sunder
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 895
  • [22] Parkinson's disease and neuroinflammation - Cellular pathology, mechanisms and therapeutic options
    Toenges, Lars
    Metzdorf, Judith
    Zella, Samis
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2018, 86 : S10 - S20
  • [23] MOLECULAR MECHANISMS OF PATHOGENESIS OF PARKINSON'S DISEASE
    Shadrina, M. I.
    Slominsky, P. A.
    Limborska, S. A.
    INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 281, 2010, 281 : 229 - 266
  • [24] Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease
    Jung, Olive
    Patnaik, Samarjit
    Marugan, Juan
    Sidransky, Ellen
    Westbroek, Wendy
    EXPERT REVIEW OF PROTEOMICS, 2016, 13 (05) : 471 - 479
  • [25] Distinct mechanisms underlying the therapeutic effects of low-molecular-weight heparin and chondroitin sulfate on Parkinson's disease
    Wang, Qingchi
    Bu, Changkai
    Wang, Haoran
    Zhang, Bin
    Chen, Qingqing
    Shi, Deling
    Chi, Lianli
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 262
  • [26] NEUROLOGICAL MANIFESTATIONS IN PAKISTANI LYSOSOMAL STORAGE DISORDERS PATIENTS AND MOLECULAR CHARACTERIZATION OF GAUCHER DISEASE
    Gul, Rutaba
    Firasat, Sabika
    Hussain, Mulazim
    Tufail, Muhammad
    Ahmad, Waheed
    Afshan, Kiran
    GENETIKA-BELGRADE, 2021, 53 (03): : 1017 - 1029
  • [27] Unraveling the Pathogenetic Mechanisms Underlying the Association between Specific Mitochondrial DNA Haplogroups and Parkinson's Disease
    Lan, Min-Yu
    Lin, Tsu-Kung
    Lace, Baiba
    Utkus, Algirdas
    Burnyte, Birute
    Grigalioniene, Kristina
    Lin, Yu-Han
    Inashkina, Inna
    Liou, Chia-Wei
    CELLS, 2024, 13 (08)
  • [28] Common Mechanisms Underlying a-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease
    Sohrabi, Tahereh
    Mirzaei-Behbahani, Behnaz
    Zadali, Ramin
    Pirhaghi, Mitra
    Morozova-Roche, Ludmilla A.
    Meratan, Ali Akbar
    JOURNAL OF MOLECULAR BIOLOGY, 2023, 435 (12)
  • [29] Cellular and molecular pathophysiology in the progression of Parkinson’s disease
    Vandana Zaman
    Donald C. Shields
    Ramsha Shams
    Kelsey P. Drasites
    Denise Matzelle
    Azizul Haque
    Narendra L. Banik
    Metabolic Brain Disease, 2021, 36 : 815 - 827
  • [30] Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review
    Angelopoulou, Efthalia
    Paudel, Yam Nath
    Papageorgiou, Sokratis G.
    Piperi, Christina
    BRAIN SCIENCES, 2022, 12 (02)